San Francisco, CA, United States of America

Tod R Smeal

USPTO Granted Patents = 2 


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2008-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Tod R Smeal

Introduction

Tod R Smeal is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the area of cancer research. With a total of 2 patents, Smeal's work focuses on diagnosing abnormal cell proliferation and developing therapeutic uses for specific biomarkers.

Latest Patents

Smeal's latest patents include innovations related to GEF-H1b, which involves biomarkers, complexes, assays, and therapeutic uses thereof. The first patent addresses the diagnosis of abnormal cell proliferation in biological samples. It also focuses on screening for drugs that can inhibit, reduce, or abolish cell growth, especially tumorigenic cell growth. This is achieved by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S. The second patent is similar in nature, reiterating the importance of GEF-H1b in diagnosing and treating abnormal cell growth.

Career Highlights

Tod R Smeal has been associated with Sugen Incorporated, where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding of cancer biology and developing potential therapeutic strategies.

Collaborations

Smeal has collaborated with notable colleagues, including Marinella G Callow and Bahija Jallal. These partnerships have enhanced the scope and impact of his research efforts.

Conclusion

Tod R Smeal's innovative work in the field of biotechnology exemplifies the critical role of inventors in advancing medical science. His patents reflect a commitment to improving cancer diagnostics and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…